These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 9923534)

  • 1. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
    Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.
    Bandak S; Goren D; Horowitz A; Tzemach D; Gabizon A
    Anticancer Drugs; 1999 Nov; 10(10):911-20. PubMed ID: 10630359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.
    Working PK; Newman MS; Sullivan T; Brunner M; Podell M; Sahenk Z; Turner N
    Toxicol Sci; 1998 Nov; 46(1):155-65. PubMed ID: 9928679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
    Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
    Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
    Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
    Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice.
    Araújo JG; Mota Ld; Leite EA; Maroni Lde C; Wainstein AJ; Coelho LG; Savassi-Rocha PR; Pereira MT; de Carvalho AT; Cardoso VN; De Oliveira MC
    Exp Biol Med (Maywood); 2011 Jul; 236(7):808-15. PubMed ID: 21685237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
    Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
    Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
    Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.